Business
INVO Bioscience Receives Registration Approval for INVOcell in Turkey
- An estimated 15% to 20% of the Turkish population suffers from the difficulty of conceiving - "As the world's only Intravaginal Culture System, INVOcell, a
About this update from Invo Fertility, Inc.
[{"type":"text","content":"- An estimated 15% to 20% of the Turkish population suffers from the difficulty of conceiving\n - \"As the world's only Intravaginal Culture System, INVOcell, a streamlined treatment solution, is uniquely positioned to address the challenges within the infertility industry.\"\n\n\nSARASOTA, Fla., July 16, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO), (\"the Company\", \"INVO\") a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, received product registration approval for INVOcell in Turkey, paving the way for commercialization efforts to begin in the country. \n\n \n \n \n \n \n \n\n \nIn November 2019, INVO Bioscience and Orcan Medical, a leading medical distributor to large medical device companies including St. Jude Medical, Cooper Surgical, and Clarus within Turkey, entered into an exclusive commercial partnership for INVOcell in Turkey. The agreement required product registration within country which has now been received. The exclusive agreement with Orcan Medical for Turkey is contingent upon minimum purchase and other requirements.\nTurkey, and the Eurasia region, has a growing middle-class population, yet is experiencing a multi-decade decline in birth rate according to The World Bank. The decline in fertility rates in Eurasia at large, and Turkey in particular, has pushed governments to allocate more resources to combating the issue. According to research, an estimated 15% to 20% of the Turkish population suffers from the difficulty of conceiving. \nSteve Shum, CEO of INVO Bioscience, commented, \"We are pleased to have achieved this important registration approval for Turkey which enables our distribution partner, Orcan Medical, to now begin commercialization efforts in the country. Similar to other regions around the world, the people of Turkey are faced with increased infertility rates and challenges to receiving treatment, including access to care and cost of treatment. As the world's only Intravaginal Culture System, INVOcell, a streamlined treatment solution, is uniquely positioned to address the challenges within the infertility industry.\"\nThe INVOcell SystemThe INVOcell system is a novel fertility treatment that uses a woman's own body as a natural incubator fo...